EVERSANA Merges with Waltz Health to Create a New Force in Pharma Commercialization and Prescription Drug Access

Combined company offers next-generation commercialization model that directly connects life sciences to payers and patients to accelerate access, improve affordability and transform drug value across the care continuum.

Waltz Health Co-founder and CEO Mark Thierer appointed CEO of EVERSANA. Jim Lang, former CEO, will continue to serve as a board member.

CHICAGO, Aug. 26, 2025 /PRNewswire/ — EVERSANA and Waltz Health today announced a merger to form a unified healthcare platform that redefines pharmaceutical commercialization and patient access. The move integrates Waltz Health’s software-powered drug-price marketplaces and direct-to-payer model into EVERSANA’s global commercialization services, creating a next-generation approach for drug access and value in the U.S. healthcare system.

EVERSANA is a pioneering leader in the pharma commercialization industry, serving the top 50 pharma and biotech companies globally with a full suite of end-to-end commercialization capabilities. By embedding Waltz Health’s technology and broad payer footprint, the combined company is positioned to break through the industry’s misaligned incentives and fragmented patient experiences. The merger will be especially impactful for lowering the cost of specialty medications and high-cost drug classes like GLP-1s. Waltz’s technology platform, including its AI-powered prescription routing and affordability solution, connects patients, health insurers, self-insured employers, governments and pharmacy benefit managers (PBMs).

Mark Thierer, Co-founder and CEO of Waltz Health and Chairman of EVERSANA, will serve as CEO of the combined organization. Thierer brings decades of leadership experience in healthcare innovation, including previously serving as CEO of OptumRx, following UnitedHealth Group’s $13 billion acquisition of Catamaran.

“This is a pivotal moment for the healthcare industry,” said Thierer. “By combining EVERSANA’s pharma services with Waltz’s technology-enabled payer solutions, we’re creating a unified platform that connects life sciences innovation directly to the organizations and individuals we’re meant to serve. This model is built to accelerate access, improve outcomes and deliver smarter, more transparent drug commercialization at every step.”

A Disruptive End-to-End Model for Life Sciences

EVERSANA has long served as the go-to partner for pharmaceutical and biotech companies navigating product launches, commercialization, market access and patient support. Waltz Health complements this strong foundation with a suite of technology-enabled solutions, ranging from AI-powered pharmacy switches and affordability tools to payer-facing marketplaces, that streamline patient access, lower drug costs for patients and plan sponsors, and greatly improve the patient experience.

The union not only connects life science companies directly to payers – including commercial insurers, self-insured employers and PBMs – it also gives them unmatched reach and execution power across:

• Pharma Commercialization: The combined organization integrates patient services, field teams, digital marketing, reimbursement support and real-world evidence – all powered by modern software infrastructure.
• Payer Connectivity: Waltz’s direct-to-payer and direct-to-patient solutions will supercharge the EVERSANA COMPLETE Commercialization™ model, giving manufacturers turnkey channels to reach millions of covered lives.
• Drug Affordability & Adherence: Together, the companies enable net-price models, copay optimization and integrated pharmacy routing that reduce patient abandonment and increase therapeutic persistence.
• Specialty Pharmacy Infrastructure: Through Waltz Connect, a technology-powered, end-to-end solution that gives payers flexibility and optimized specialty pharmacy savings by unlocking competition, Eversana now has a fully integrated, URAC-accredited specialty pharmacy network designed for high-cost therapies and limited distribution drugs.

A New Standard for Drug Value

The merger comes at a time when the pharmaceutical industry is facing increasing pressure over drug pricing, patient affordability and channel inefficiencies. The new organization aims to address these issues head-on with a value-focused model that balances innovation, transparency and access across the entire lifecycle of care.

“This combination brings together the scale and services of EVERSANA with Waltz Health’s payer-integrated platforms to create a company purpose-built for the future of life sciences,” said Thierer. “Together, we are launching a new-to-the-world model that directly connects manufacturers to patients and payers, delivering significant cost savings and improved patient outcomes to the healthcare system.”

Unmatched Industry Leadership

Waltz Health’s leadership team has been at the forefront of innovation, building technology that now serves as a foundation of the prescription benefit landscape today. EVERSANA brings a deep bench of pharmaceutical commercialization expertise, delivering high-value solutions across the life sciences landscape. Together, this combined leadership team is poised to redefine the pharmaceutical supply chain and drive its next chapter of transformation.

About EVERSANA®

EVERSANA® is a leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and X.

About Waltz Health

Waltz Health is a digital health company developing technologies and services that support better-informed decisions on prescription care. Designed for payers, pharmacies, pharmacy benefit managers and self-insured employers, the company offers AI-driven marketplaces to lower overall drug costs, providing better pricing options and more information for consumers while also helping payers take control of their pharmacy benefits. Founded in 2021 by Mark Thierer and Jonathon Thierer, Waltz Health is headquartered in Chicago and is backed by GV, Define Ventures, Echo Health Ventures, Blue Venture Fund, Byers Capital and Twine Ventures. For more information, visit www.waltzhealth.com.

Contacts

Sam Moore
press@waltzhealth.com

Matt Braun
matt.braun@eversana.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/eversana-merges-with-waltz-health-to-create-a-new-force-in-pharma-commercialization-and-prescription-drug-access-302538273.html

SOURCE EVERSANA; Waltz Health